Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5347666 | 0.99 | CCR5 (0.76) | CCR5CYP3A4CYP2C9CHRM3SIGMAR1 | |
| SCHEMBL5349529 | 0.96 | CCR5 (0.80) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5339736 | 0.95 | CCR5 (0.81) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5340545 | 0.94 | CCR5 (0.80) | CCR5CYP3A4CYP2C9 | |
| SCHEMBL5355861 | 0.94 | CCR5 (0.80) | CCR5CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5339961 | 0.93 | CCR5 (0.80) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5343178 | 0.93 | CCR5 (0.80) | CCR5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6013285 | 0.91 | CCR5 (0.79) | CCR5CYP3A4CYP2C9CHRM3SIGMAR1 | |
| SCHEMBL5344202 | 0.90 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL5346686 | 0.89 | CCR5 (0.85) | CCR5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | claimed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | claimed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | claimed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7053090-B2 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | disclosed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ACKR3, CXCR5, CCL11 | CCR5 4/4885CYP3A4 641/4885CYP2C9 642/4885 |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ACKR3, CCL11, CCR7 | CCR5 5/4885CYP3A4 1049/4885CYP2C9 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.